Wedge Capital Management L L P NC Sells 23,165 Shares of Ralliant Corporation $RAL

Wedge Capital Management L L P NC reduced its stake in Ralliant Corporation (NYSE:RAL) by 39.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 36,123 shares of the company’s stock after selling 23,165 shares during the period. Wedge Capital Management L L P NC’s holdings in Ralliant were worth $1,580,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of RAL. ST Germain D J Co. Inc. purchased a new position in shares of Ralliant during the second quarter valued at about $27,000. Manchester Capital Management LLC purchased a new position in Ralliant during the 2nd quarter valued at approximately $29,000. Evermay Wealth Management LLC bought a new stake in Ralliant in the 2nd quarter worth approximately $32,000. SouthState Corp purchased a new stake in shares of Ralliant during the 2nd quarter worth approximately $35,000. Finally, Nomura Asset Management Co. Ltd. bought a new position in shares of Ralliant during the 2nd quarter valued at approximately $38,000.

Ralliant Trading Down 0.2%

Ralliant stock opened at $51.64 on Wednesday. Ralliant Corporation has a 12-month low of $40.70 and a 12-month high of $55.08. The company has a quick ratio of 1.03, a current ratio of 1.49 and a debt-to-equity ratio of 0.39. The business has a 50-day moving average price of $47.14. The company has a market cap of $5.83 billion and a price-to-earnings ratio of 40.66.

Ralliant (NYSE:RAL) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.02. The firm had revenue of $529.10 million during the quarter, compared to analysts’ expectations of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 23rd. Investors of record on Monday, December 8th were paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Monday, December 8th. Ralliant’s dividend payout ratio (DPR) is currently 15.75%.

Analyst Ratings Changes

A number of research firms recently issued reports on RAL. Morgan Stanley began coverage on shares of Ralliant in a research note on Tuesday, September 2nd. They set an “overweight” rating and a $55.00 price target on the stock. Oppenheimer boosted their target price on shares of Ralliant from $55.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Royal Bank Of Canada upped their target price on shares of Ralliant from $45.00 to $52.00 and gave the company a “sector perform” rating in a research report on Friday, November 7th. Truist Financial initiated coverage on Ralliant in a research report on Friday, December 12th. They issued a “buy” rating and a $62.00 price target for the company. Finally, Citigroup raised Ralliant from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $53.00 to $61.00 in a research note on Monday, December 8th. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $57.89.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.